Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis
- PMID: 29505863
- DOI: 10.1016/j.jaad.2018.02.058
Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis
Abstract
Background: It is unknown whether treatment costs for keratinocyte carcinoma (KC) and actinic keratosis (AK) can be lowered by spending more on chemoprevention.
Objective: To examine the impact of 1-course treatment with topical fluorouracil (5-FU) on the face and ears on KC and AK treatment costs over 3 years.
Methods: The Veterans Affairs Keratinocyte Carcinoma Chemoprevention trial compared the efficacy of topical 5-FU 5% with that of vehicle control cream for reducing KC risk. Trial data and administrative data on costs and utilization were analyzed to measure postrandomization encounters and treatment costs for KC and AK care. Adjusted models were used to test for statistically significant differences between treatment arms for number of treatment encounters and costs.
Results: One year after randomization, the control arm had a higher mean number of treatment encounters for squamous cell carcinoma (0.04) than the intervention arm (0.01) (P < .01). At 1 year, the intervention arm had lower treatment and dermatologic costs: $2106 (standard deviation, $2079) compared with $2444 (standard deviation, $2716) for the control patients (P = .02). After 3 years, the intervention arm incurred a cost of $771 less per patient.
Limitations: Care not provided or paid for by the Department of Veterans Affairs was not included. Results may not be generalizable to other payers.
Conclusion: We found significant cost savings for patients treated with 5-FU.
Keywords: actinic keratosis; basal cell carcinoma; costs; squamous cell carcinoma; squamous cell carcinoma in situ; veterans.
Published by Elsevier Inc.
Similar articles
-
Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial.JAMA Dermatol. 2018 Feb 1;154(2):167-174. doi: 10.1001/jamadermatol.2017.3631. JAMA Dermatol. 2018. PMID: 29299592 Free PMC article. Clinical Trial.
-
Costs of Keratinocyte Carcinoma (Nonmelanoma Skin Cancer) and Actinic Keratosis Treatment in the Veterans Health Administration.Dermatol Surg. 2016 Sep;42(9):1041-7. doi: 10.1097/DSS.0000000000000820. Dermatol Surg. 2016. PMID: 27465252
-
Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.JAMA Dermatol. 2015 Sep;151(9):952-60. doi: 10.1001/jamadermatol.2015.0502. JAMA Dermatol. 2015. PMID: 25950503 Clinical Trial.
-
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders.J Dermatolog Treat. 2009;20(6):328-35. doi: 10.3109/09546630902789326. J Dermatolog Treat. 2009. PMID: 19954388 Review.
-
Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule.Cutis. 2004 Dec;74(6 Suppl):18-23. Cutis. 2004. PMID: 15666898 Review.
Cited by
-
Accelerating patient recruitment using social media: Early adopter experience from a good clinical practice-monitored randomized controlled phase I/IIa clinical trial on actinic keratosis.Contemp Clin Trials Commun. 2023 Dec 20;37:101245. doi: 10.1016/j.conctc.2023.101245. eCollection 2024 Feb. Contemp Clin Trials Commun. 2023. PMID: 38234709 Free PMC article.
-
Recent Advances in Clinical Research for Skin Cancer Chemoprevention.Cancers (Basel). 2023 Jul 27;15(15):3819. doi: 10.3390/cancers15153819. Cancers (Basel). 2023. PMID: 37568635 Free PMC article. Review.
-
Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.Int J Mol Sci. 2023 Mar 5;24(5):4989. doi: 10.3390/ijms24054989. Int J Mol Sci. 2023. PMID: 36902419 Free PMC article. Review.
-
Topical application of gemcitabine generates microvesicle particles in human and murine skin.Biofactors. 2022 Nov;48(6):1295-1304. doi: 10.1002/biof.1924. Epub 2022 Dec 12. Biofactors. 2022. PMID: 36504167 Free PMC article.
-
Management Pearls on the Treatment of Actinic Keratoses and Field Cancerization.Dermatol Ther (Heidelb). 2020 Oct;10(5):903-915. doi: 10.1007/s13555-020-00425-4. Epub 2020 Jul 17. Dermatol Ther (Heidelb). 2020. PMID: 32681454 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
